Interfering with Hemostatic System Components: Possible New Approaches to Antiangiogenic Therapy

Marek Z. Wojtukiewicz; Ewa Sierko; Leo R. Zacharski

doi:10.1055/s-2004-822979

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2004; 30(1): 145-156
DOI: 10.1055/s-2004-822979

Interfering with Hemostatic System Components: Possible New Approaches to Antiangiogenic Therapy

Marek Z. Wojtukiewicz¹ ^, ² , Ewa Sierko² , Leo R. Zacharski³

¹Professor
²Department of Oncology, Medical University, Bialystok, Poland
³Veterans Administration and Regional Office, White River Junction, and the Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire

Abstract

Inhibition of angiogenesis has progressed from a theoretical and esoteric discipline scrutinized in but a few laboratories far removed from the clinic, to mainstream experimental clinical cancer therapeutics. Dramatic progress in this field represents a triumph of the concept of translational biomedical research. Growth of knowledge in this discipline has brought to light a bewildering yet tantalizing array of interacting enzymatic algorithms that participate in the highly orchestrated process of new blood vessel formation critical for tumor growth and dissemination. It is clear that pathways of blood coagulation (in broad context) and angiogenesis are inextricably linked. The facts that much is already known about many components of these pathways and that stalling of tumor growth has already been demonstrated for several interventions aimed at participants in these reactions send a clear signal that more effective and less toxic cancer therapy may be at hand in the near future. There is no lack of candidate targets for intervention brought to light by preclinical scientists. Numerous well-characterized investigational agents are on hand for testing. The challenge is clearly in the hands of the clinical investigators to proceed with human intervention studies while armed with knowledge of opportunities and pitfalls that should guide insightful clinical trial design. A particularly compelling feature of this treatment paradigm is that it is not aimed directly at distruction of tumor through inhibition of the DNA replication machinery of the cell. Rather it is aimed at restoring the normal state by modulating the dysregulated interaction of tumor cells with their environment that is characteristic of cancer.

KEYWORDS

Cancer - hemostasis - angiogenesis - cancer therapy - angiogenesis inhibitors

Full Text

References

REFERENCES

1 Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285 1182-1186
2 Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to the clinic. Thromb Haemost. 2001; 86 23-33
3 Holash J, Maisonpierre P C, Compton D et al.. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999; 284 1994-1998
4 Dvorak H F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002; 20 4368-4380
5 Lyden D, Hattori K, Dias S et al.. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001; 7 1194-1201
6 Rak J W, St Croix B D, Kerbel R S. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs. 1995; 6 3-18
7 Wojtukiewicz M Z, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia. 2001; 3 371-384
8 Holmgren L, O'Reilly M S, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995; 1 149-153
9 O'Reilly M S, Boehm T, Shing Y et al.. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88 277-285
10 Dameron K M, Volpert O V, Tainsky M A, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994; 265 1582-1584
11 Kerbel R S. Inhibition of tumor angiogenesis as a strategy to circumvent resistance to anticancer therapeutic agents. Bioessays. 1991; 13 31-36
12 Boehm T, Folkman J, Browder T, O'Reilly M S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997; 390 404-407
13 Yang J C, Haworth L, Sherry R M et al.. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349 427-434
14 Kuenen B C, Tabernero J, Baselga J et al.. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res. 2003; 9 1648-1655
15 Albanell J, Codony J, Rovira A et al.. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003; 532 253-268
16 Hurwitz H, Fehrenbacher L, Cartwright T et al.. Bevacizumab (Avastin, a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. In: Program and abstracts of the 39th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, IL;
17 Burstein H J, Parker L M, Savoie J et al.. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. In: Program and abstracts of the 25th Annual San Antonio Breast Cancer Symposium; December 11-14, 2002; San Antonio, TX;
18 Viloria-Petit A, Crombet T, Jothy S et al.. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001; 61 5090-5101
19 Relf M, LeJeune S, Scott P A et al.. Expression of the angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997; 57 963-969
20 Yu J L, Rak J W, Carmeliet P, Nagy A, Kerbel R S, Coomber B L. Heterogeneous vascular dependence of tumor cell populations. Am J Pathol. 2001; 158 1325-1334
21 Kerbel R S, Yu J, Tran J et al.. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 2001; 20 79-86
22 Kerbel R S, Viloria-Petit A, Klement G, Rak J. ‘Accidental’ anti-angiogenic drugs, anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer. 2000; 36 1248-1257
23 Hahnfeldt P, Folkman J, Hlatky L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol. 2003; 220 545-554
24 Cao Y. Endogenous angiogenesis inhibitors: angiostatin, endostatin and other proteolytic fragments. Prog Mol Subcell Biol. 1998; 20 161-176
25 O'Reilly M S, Holmgren L, Shing Y et al.. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by Lewis lung carcinoma. Cell. 1994; 79 315-328
26 Jung S P, Siegrist B, Hornick C A et al.. Effect of human recombinant Endostatin protein on human angiogenesis. Angiogenesis. 2002; 5 111-118
27 O'Reilly M S, Holmgreen L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996; 2 689-692
28 Soff G A, Hong J, Fishman D et al.. Angiostatin 4.5′: a naturally occurring human angiogenesis inhibitor. Blood. 1998; 92(suppl) 174a , (abst)
29 Cao R, Wu H L, Veitonmaki N et al.. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA. 1999; 96 5728-5733
30 Cao Y. Therapeutic potentials of angiostatin in the treatment of cancer. Haematologica. 1999; 84 643-650
31 Prox D, Becker C, Pirie-Shepard S R, Celik I, Folkman J, Kisker O. Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg. 2003; 27 405-411
32 Folkman J. Role of angiogenesis in tumor and metastasis. Semin Oncol. 2002; 29 15-18
33 Galaup A, Opolon P, Bouquet C et al.. Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model. Mol Ther. 2003; 7 731-740
34 Mauceri H J, Seetharam S, Beckett M A et al.. Angiostatin potentiates cyclophosphamide treatment of metastatic disease. Cancer Chemother Pharmacol. 2002; 50 412-418
35 Camhausen K, Moses M A, Beecken W D, Khan M K, Folkman J, O'Reilly M S. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 2001; 61 2207-2211
36 Mauceri H J, Hanna N N, Beckett M A et al.. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature. 1998; 394 287-291
37 Gorski D H, Mauceri H J, Salloum R M et al.. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 1998; 58 5686-5689
38 Sim B KL, MacDonald N J, Gubish E R. Angiostatin and endostatin: endogenous inhibitors of tumor growth. Cancer Metastasis Rev. 2000; 19 181-190
39 Mundhenke C, Thomas J P, Wilding G et al.. Tissue examination to monitor antiangiogenic therapy: a phase I trial with endostatin. Clin Cancer Res. 2001; 7 3366-3374
40 Eder Jr J P, Supko J G, Clark J W et al.. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002; 20 3772-3784
41 Feldman A L, Libutti S K. Progress in antiangiogenic gene therapy of cancer. Cancer. 2000; 89 1181-1194
42 Matsuda K M, Madoiwa S, Hasumi Y et al.. A novel strategy for the tumor angiogenesis-targeted gene therapy: generation of angiostatin from endogenous plasminogen by protease gene transfer. Cancer Gene Ther. 2000; 7 589-596
43 Gorrin-Rivas M J, Arii S, Furutani M et al.. Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin Cancer Res. 2000; 6 1647-1654
44 Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as regulator of angiogenesis. J Biol Chem. 2000; 275 1521-1524
45 Lee T H, RhimTH, Kim S S. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells. J Biol Chem. 1998; 273 28805-28812
46 Rhim T H, Park C S, Kim E, Kim S S. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth. Biochem Biophys Res Commun. 1998; 252 513-516
47 Gupta S K, Hassel T, Singh J P. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA. 1995; 92 7799-7803
48 O'Reilly M S, Pirie-Shepherd S, Lane W S, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science. 1999; 285 1926-1928
49 Kisker O, Onizuka S, Banyard J et al.. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res. 2001; 61 7298-7304
50 Larsson H, Sjoblom T, Dixelius J et al.. Antiangiogenic effects of latent antithrombin through perturbated cell-matrix interactions and apoptosis of endothelial cells. Cancer Res. 2000; 60 6723-6729
51 Larsson H, Akerud P, Nordling K, Rauh-Segall E, Claesson-Welsh L, Bjork I. A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. J Biol Chem. 2001; 276 11996-12002
52 Pahl M V, Vaziri N D, Oveisi F, Wang J, Ding Y. Antithrombin III inhibits mesangial cell proliferation. J Am Soc Nephrol. 1996; 7 2249-2253
53 Souter P J, Thomas S, Hubbard A R, Poole S, Römisch J, Gray E. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med. 2001; 29 134-139
54 Bombeli T, Mueller M, Haeberii A. Anticoagulant properties of the vascular endothelium. Thromb Haemost. 1997; 77 408-423
55 Sato Y, Shimada H, Takaki R. Autocrinological role of basic fibroblast growth factor on tube formation of vascular endothelial cells in vitro. Biochem Biophys Res Commun. 1991; 180 1098-1102
56 Pluda J M, Parkinson D R. Clinical implications of tumor-associated neovascularisation and current antiangiogenic strategies for the treatment of malignancies of pancreas. Cancer. 1996; 78(suppl) 680-687
57 Gengrinovitch S, Greenberg S M, Cohen T et al.. Platelet factor-4 inhibits the mitogenic activity of VEGF¹²¹ and VEGF¹⁶⁵ using several concurrent mechanisms. J Biol Chem. 1995; 270 15059-15065
58 Perollet C, Han Z C, Savona C, Caen J P, Bikfalvi A. Platelet factor-4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood. 1998; 91 3289-3299
59 Hampl M, Tanaka T, Albert P S, Lee J, Ferrari N, Fine H A. Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites. Hum Gene Ther. 2001; 12 1713-1729
60 Callendar N S, Varki N, Rao L V. Immunohistochemical identification of tissue factor in solid tumors. Cancer. 1992; 70 1194-1201
61 Rao L VM. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev. 1992; 11 249-266
62 Zacharski L R, Wojtukiewicz M Z, Costantini V, Ornstein D L, Memoli V A. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost. 1992; 18 104-116
63 Rottingen J A, Enden T, Camerer E, Iversen J G, Prydz H. Binding of human factor VIIa to tissue factor induces Ca²⁺ signals in J82 cells, transfected COS-1 cells, MDCK cells and in human endothelial cells induced to synthesize tissue factor. J Biol Chem. 1995; 270 4650-4660
64 Camerer E, Rottingen J A, Iversen J G, Prydz H. Coagulation factors VII and X induce Ca²⁺ oscillations in Madin-Darby canine kidney cells only when proteolytically active. J Biol Chem. 1996; 271 29034-29042
65 Prydz H, Camerer E, Rottingen J A, Wiiger M T, Gjernes E. Cellular consequences of the initiation of blood coagulation. Thromb Haemost. 1999; 82 183-192
66 Sorensen B B, Freskgard P O, Nielsen L S, Rao L V, Ezban M, Peterson L C. Factor VIIa-induced p44/42 mitogen-activated protein activation requires the proteolytic activity of factor VIIa and is independent of the tissue factor cytoplasmic domain. J Biol Chem. 1999; 274 21349-21354
67 Versteeg H H, Hoedemaeker I, Diks S H et al.. Factor VIIa/tissue factor-induced signaling via the activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac. J Biol Chem. 2000; 275 28750-28756
68 Ollivier V, Bentolila S, Chabbat J, Hakim J, Prost D. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood. 1998; 91 2698-2703
69 Ollivier V, Chabbat J, Herbert J M, Hakim J, de Prost D. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa. Arterioscler Thromb Vasc Biol. 2000; 20 1374-1381
70 Abe K, Shoji M, Chen J et al.. Regulation of vascular endothelial growth production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA. 1999; 96 8663-8668
71 Zioncheck T F, Roy S, Vehar G A. The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism. J Biol Chem. 1992; 267 3561-3564
72 Zhang Y, Deng Y, Luther T et al.. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994; 94 1320-1327
73 Shoji M, Abe K, Nawroth P P, Rickles R. Molecular mechanisms linking thrombosis and angiogenesis in cancer. Trends Cardiovasc Med. 1997; 7 52-59
74 Contrino J, Hair G, Kreutzer D L, Rickles F R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996; 2 209-215
75 Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T. Tissue factor, osteopontin, α_vβ₃ integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer. 2000; 82 1967-1973
76 Koomagi R, Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer. 1998; 79 19-22
77 Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer. 2000; 83 164-170
78 Bajaj M S, Bajaj S P. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost. 1997; 78 471-477
79 Bromberg M E, Capello M. Cancer and blood coagulation: molecular aspects. Cancer J. 1999; 5 132-138
80 Preissner K T. Hemostatic protease receptors and endothelial cell function: insights from gene targeting in mice. Semin Thromb Hemost. 2000; 26 451-461
81 Fernandez Pujol B, Lucibello F C, Gehling U M. Endothelial-like cells derived from human CD14 positive monocytes. Differentiation. 2000; 65 287-300
82 Gude R P, Binda M M, Boquete A L, Bonfil R D. Inhibition of endothelial cell proliferation and tumor-induced angiogenesis by pentoxifylline. J Cancer Res Clin Oncol. 2001; 127 625-630
83 Amirkhosravi A, Meyer T, Warnes G et al.. Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor. Thromb Haemost. 1998; 80 598-602
84 Vincent L, Chen W, Hong L et al.. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett. 2001; 495 159-166
85 Kureishi Y, Luo Z, Shiojima I et al.. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000; 6 1004-1010
86 Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand J L, Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res. 2001; 89 866-873
87 Weis M, Heeschen C, Glassford A J, Cooke J P. Statins have biphasic effects on angiogenesis. Circulation. 2002; 105 739-745
88 Fenton 2nd J W, Shen G X, Minnear F L et al.. Statins induce hypothrombotic states?. Clin Appl Thromb Hemost. 2000; 6 18-21
89 Golino P, Ragini M, Cirillo P et al.. Antithrombotic effects of recombinant human active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ Res. 1998; 82 39-46
90 Clauss M. Molecular biology of the VEGF and the VEGF receptor family [review]. Semin Thromb Hemost. 2000; 26 561-569
91 Rosen L. Antiangiogenic strategies and agents in clinical trials [review]. Oncologist. 2000; 5(suppl 1) 20-27
92 Svidhar S S, Shepherd F A. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer. 2003; 42(suppl 1) 581-591
93 Rapaport S I, Rao L VM. The tissue factor pathway: how it become a “Prima Ballerina”. Thromb Haemost. 1995; 74 7-17
94 Mousa S A, Mohamed S. Anti-angiogenesis efficacy of the low molecular weight heparin (LMWH) tinzaparin and tissue factor pathway inhibitor (TFPI). Blood. 1999; 94(suppl) , 22a, 82-I (Abst)
95 Amirkhosravi A, Francis J, Mousa S A. Anti-metastatic effect of the low molecular weight heparin (LMWH) tinzaparin and tissue factor pathway inhibitor (TFPI). Thromb Haemost. 2001; 15 149,-A118 , (Abst)
96 Bajaj M S, Bajaj S P. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost. 1997; 78 471-477
97 Rao C N, Cook B, Liu Y et al.. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. Int J Cancer. 1998; 76 749-756
98 Rao C N, Mohanam S, Puppala A, Rao J S. Regulation of pro-MMP-1 and pro-MMP-3 activation by tissue factor pathway inhibitor-2/matrix associated serine protease inhibitor. Biochem Biophys Res Commun. 1999; 255 94-98
99 Iino M, Foster D C, Kisiel W. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler Thromb Vasc Biol. 1998; 18 40-46
100 Wojtukiewicz M Z, Sierko E, Zimnoch L, Kozlowski L, Kisiel W. Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost. 2003; 90 140-146
101 Zacharski L R, Costantini V, Wojtukiewicz M Z, Memoli V A, Kudryk B J. Anticoagulants as cancer therapy. Semin Oncol. 1990; 17 217-227
102 Tsopanoglou N E, Pipili-Synestos E, Maragoudakis M E. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am J Physiol. 1993; 264 1302-1307
103 Möhle R, Green D, Moore M AS, Nachman R L, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA. 1997; 94 663-668
104 Wojtukiewicz M Z, Tang D G, Ben-Josef E, Renaud C, Walz D A, Honn K V. Solid tumor cells express functional “tethered-ligand” thrombin receptor. Cancer Res. 1995; 55 698-704
105 Ukropec J A, Hollinger M K, Salva S M, Woolkalis M J. SHP2 association with VE-cadherin complexes in human endothelial cells is regulated by thrombin. J Biol Chem. 2000; 275 5983-5986
106 Belloni P N, Carney D H, Nicolson G L. Organ-derived microvessel endothelial cells exhibit differential responsiveness to thrombin and other growth factors. Microvasc Res. 1992; 43 20-45
107 Wojtukiewicz M Z, Tang D G, Nelson K K, Walz D A, Diglio C A, Honn K V. Thrombin enhances tumor cell adhesive and metastatic properties via increased αIIbβ3 expression on the cell surface. Thromb Res. 1992; 68 233-245
108 BenEzra M, Vlodavsky I, Ishai-Michaeli R, Neufeld G, Bar-Shavit R. Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix. Blood. 1993; 81 3324-3331
109 Tsopanoglou N E, Maragoudakis M E. On the mechanism of thrombin-induced angiogenesis. J Biol Chem. 1999; 274 23969-23976
110 Markwardt F. Development of direct thrombin inhibitors in comparison with glycosaminoglycans. Semin Thromb Hemost. 2001; 27 523-530
111 Hassan A AK, Amenta S, Schmaier A H. Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of α-thrombin-induced platelet activation. Circulation. 1996; 94 517-528
112 Hassan A A, Warnock M, Srikanth S, Schmaier A H. Developing peptide inhibitors to thrombin activation of platelets from bradykinin analogs. Thromb Res. 2001; 104 451-465
113 Bahou W F, Coller B S, Potter C L, Norton K J, Kutok J L, Goligorsky M S. The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation. J Clin Invest. 1993; 91 1405-1413
114 Cook J J, Sitko G R, Bednar B et al.. An antibody against the exo-site of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation. 1995; 91 2961-2971
115 Derian C K, Maryanoff B E, Zhang H-C, Andrade-Gordon P. Therapeutic potential of protease-activated receptor-1 antagonists. Expert Opin Investig Drugs. 2003; 12 209-221
116 Engelberg H. Action of heparin that may affect the malignant process. Cancer. 1999; 85 257-272
117 Hull R D, Raskob G E, Pineo G F et al.. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992; 326 975-982
118 Prandoni P, Lensing A WA, Büller H R et al.. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992; 339 441-445
119 Hirsh J, Siragusa S, Cosmi B, Ginsberg J S. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost. 1995; 74 360-363
120 Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg J S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med. 1996; 100 269-277
121 Norrby K. Heparin and angiogenesis: a low-molecular-weight-fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis. 1993; 23(suppl 1) 141-149
122 Norrby K, Østergaard P. A 5.0-kD heparin fraction systemically suppresses VEGF¹⁶⁵-mediated angiogenesis. Int J Microcirc Clin Exp. 1997; 17 314-321
123 Norrby K, Østergaard P. Basic fibroblast growth factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp. 1996; 16 8-15
124 Lepri A, Benelli U, Bernardini N et al.. Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. J Ocul Pharmacol. 1994; 10 273-280
125 Folkman J, Langer R, Linhardt R J, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science. 1983; 221 719-725
126 Jacobson A M, Hahnenberger R. Antiangiogenic effect of heparin and other sulphated glycosaminoglycans in the chick chorioallantoic membrane. Pharmacol Toxicol. 1991; 69 122-126
127 Norrby K. 2.5 kD and 5 kD heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF¹⁶⁵-mediated mammalian angiogenesis. Int J Exp Pathol. 2000; 81 191-198
128 Sasisekharan R, Ernst S, Venkataraman G. On the regulation of fibroblast growth factor activity by heparin-like glycosaminoglycans. Angiogenesis. 1997; 1 45-54
129 Colin S, Jeanny J C, Mascarelli F et al.. In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor. Mol Pharmacol. 1999; 55 74-82
130 Saksela O, Moscatelli D, Sommer A, Rifkin D B. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol. 1988; 107 743-751
131 Rusnati M, Presta M. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. Int J Clin Lab Res. 1996; 26 15-23
132 Presta M, Maier J A, Rusnati M, Ragnotti G. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J Cell Physiol. 1989; 140 68-74
133 Ishai-Michaeli R, Eldor A, Vlodavsky I. Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Regul. 1990; 1 833-842
134 Vlodavsky I, Ishai-Michaeli R, Mohsen M et al.. Modulation of neovascularization and metastasis by species of heparin. Adv Exp Med Biol. 1992; 313 317-327
135 Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I. A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane. Am J Pathol. 1988; 130 393-400
136 D'Amore P A. Heparin-endothelial cell interactions. Haemostasis. 1990; 20(suppl 1) 159-165
137 Taniguchi T, Toi M, Tominaga T. Rapid induction of hepatocyte growth factor by heparin. Lancet. 1994; 344 470
138 Yamazaki H, Oi H, Matsushita M et al.. Heparin induces rapid and remarkable elevation of hepatocyte growth factor/scatter factor during trans arterial embolization of renal cell carcinoma. Anticancer Res. 1997; 17 1435-1437
139 Mason I J. The ins and outs of fibroblast growth factors. Cell. 1994; 78 547-552
140 Tessler S, Rockwell P, Hicklin D et al.. Heparin modulates the interaction of VEGF¹⁶⁵ with soluble and cell associated flk-1 receptors. J Biol Chem. 1994; 269 12456-12461
141 Schlessinger J, Lax I, Lemmon M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors?. Cell. 1995; 83 357-360
142 Soker S, Goldstaub D, Svahn C M, Vlodavsky I, Levi B Z, Neufeld G. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF¹⁶⁵ to its receptors. Biochem Biophys Res Commun. 1994; 203 1339-1347
143 Jayson G C, Gallagher J T. Heparin oligosaccharides: Inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer. 1997; 75 9-16
144 Pinedo H M, Verheul H MW, D'Amato R J, Folkman J. Involvement of platelets in tumor angiogenesis?. Lancet. 1998; 352 1775-1777
145 Verheul H MW, Hoekman K, Lupu F et al.. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res. 2000; 6 166-171
146 Edwards R L, Rickles F R, Moritz T E et al.. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol. 1987; 88 596-602
147 Verheul H MW, Hoekman K, Luykx-de Bakker S et al.. Platelet transporter of vascular endothelial growth factor. Clin Cancer Res. 1997; 3 2187-2190
148 Brunner G, Nguyen H, Gabrilove J et al.. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood. 1993; 81 631-638
149 Nakamura T, Teramoto H, Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary culture. Proc Natl Acad Sci USA. 1986; 83 6489-6493
150 Griffiths L, Stratford I J. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy. Br J Cancer. 1997; 76 689-693
151 Good D J, Polverini P J, Rastinejad F et al.. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistiguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA. 1990; 87 6624-6628
152 Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature. 1982; 297 307-312
153 Selheim F, Holmsen H, Vassbotn F S. Identification of functional VEGF receptors on human platelets. FEBS Lett. 2002; 512 107-110
154 Sawicki G, Salas E, Murat J et al.. Release of gelatinase A during platelet activation mediates aggregation. Nature. 1997; 386 616-619
155 Menashi S, He L, Soria C et al.. Modulation of endothelial cells fibrinolytic activity by platelets. Thromb Haemost. 1991; 65 77-81
156 Belloc C, Lu H, Soria C et al.. The effect of platelets on invasiveness and protease production of human mammary tumor cells. Int J Cancer. 1995; 60 413-417
157 Mandriota S J, Seghezzi G, Vassali J D et al.. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem. 1995; 270 9709-9716
158 Friesel R E, Maciag T. Fibroblast growth factor prototype release and fibroblast growth factor receptor signaling. Thromb Haemost. 1999; 82 748-754
159 Honn K V, Tang G T, Chen Y Q. Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost. 1992; 18 392-415
160 Felding-Habermann B, O'Toole T E, Smith J W et al.. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA. 2001; 98 1853-1858
161 Coller B S, Peerschke E L, Scudder L E, Sullivan C A. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983; 72 325-328
162 Coller B S. Anti-GpIIb/IIIa drugs: current strategies and future directions. Thromb Haemost. 2001; 86 427-443
163 Nierodzik M L, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost. 1995; 74 282-290
164 Amirkhosravi A, Amaya M, Siddiqui F et al.. Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor-cell-activated platelets and experimental metastasis. Platelets. 1999; 10 285-292
165 Trikha M, Zhou Z, Jordan J, Nakada M T. ReoPro and m7E3 F(ab′)₂ inhibit β3 integrin mediated tumor growth and angiogenesis. Proc Am Assoc Cancer Res. 2000; 42 824,-A3678
166 Butenas S, Cawthern K, Veer C et al.. Antiplatelet agents in tissue factor-induced blood coagulation. Blood. 2001; 97 2314-2322
167 Waltermann A, Wolzt M, Petersmann K et al.. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol. 1999; 19 1757-1760
168 Borsig L, Wong R, Feramisco J et al.. Heparin and cancer revised: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA. 2001; 98 3352-3357
169 Ma L, Elliott S N, Ciriano G et al.. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA. 2001; 98 6470-6475
170 Foekens J A, Peters H A, Look M P et al.. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000; 60 636-643
171 Kuhn W, Schmalfeld B, Reuning U et al.. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIC. Br J Cancer. 1999; 79 1746-1751
172 Witte J H, Sweep C GJ, Klijn J GM et al.. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer. 1999; 80 286-294
173 Schleef R R, Loskutoff D J. Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. Haemostasis. 1988; 18 328-341
174 Kroon M E, Koolwijk P, van Goor H et al.. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. Am J Pathol. 1999; 154 1731-1742
175 Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost. 1999; 82 298-304
176 Bajou K, Noel A, Gerard R D et al.. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularisation. Nat Med. 1998; 4 923-927
177 Carmeliet P, Moons L, Dewerchin A et al.. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and plasminogen system. Ann NY Acad Sci. 1997; 811 191-206
178 Heymans S, Luttun A, Nuyens D et al.. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999; 5 1135-1142
179 Overall C M, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002; 2 657-672
180 Mandelli F, Diverio D, Avvisati G et al.. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malottie Ematologiche Maligna dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997; 90 1014-1021
181 Horne III M K, Figg W D, Arlen P et al.. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy. 2003; 23 315-318
182 Desai A A, Vogelzang N J, Rini B I, Ansari R, Krauss S, Stadler W M. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002; 95 1629-1636
183 Wun T, Law L, Harvey D, Sieracki B, Scudder S A, Ryu J K. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer. 2003; 98 1514-1520
184 Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003; 21 3665-3675
185 Lee A Y, Levine M N. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost. 1999; 25 137-145
186 Khushal A, Quinlan D, Alikhan R, Gardner J, Bailey C, Cohen A. Thromboembolic disease in surgery for malignancy-rationale for prolonged thromboprophylaxis. Semin Thromb Hemost. 2002; 28 569-576
187 Zacharski L R. Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy. Cancer Lett. 2002; 186 1-9
188 Zacharski L R. Malignancy as a solid phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Semin Thromb Hemost. 2003; 29 239-246

Marek Z WojtukiewiczM.D.

Department of Oncology, Medical University

12 Ogrodowa St, 15-027 Bialystok, Poland

Email: mwojtuk@polbox.com